← Browse by Condition
Medical Condition

astrocytoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for astrocytoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — astrocytoma Clinical Trials

How many clinical trials are currently recruiting for astrocytoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for astrocytoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for astrocytoma?
astrocytoma research spans Phase 1 (2 trials), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a astrocytoma clinical trial?
Eligibility criteria for astrocytoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Phase 3
1
Top Sponsors
National Cancer Institute (NCI) 1 trial
Sun Yat-sen University 1 trial
University of Vermont Medical Center 1 trial
Oliver Jonas 1 trial

Recruiting Clinical Trials

NCT06344130 Phase 1
Recruiting
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Enrollment
28 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT01649830 Phase 3
Recruiting
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Enrollment
290 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT05683808 Phase 2
Recruiting
Venous Thromboembolism Prevention in Outpatients With Glioma
Enrollment
40 pts
Location
United States
Sponsor
University of Vermont Medical ...
View Trial →
NCT04135807 EARLY_Phase 1
Recruiting
Implantable Microdevice In Primary Brain Tumors
Enrollment
12 pts
Location
United States
Sponsor
Oliver Jonas
View Trial →

Related Conditions

glioblastoma (2) glioma (1) recurrent glioblastoma (1) oligodendroglioma (1) oligodendroastrocytoma (1) venous thromboembolism (1) grade ii glioma (1) grade iii glioma (1) grade iv glioma (1) oligodendroglioma of brain (1) anaplastic astrocytoma of brain (1) anaplastic oligodendroglioma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology